ClinicalTrialsFinder
RecruitingNot ApplicableNCT06853886

Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation

Sponsor

University Hospital, Limoges

Enrollment

140 participants

Start Date

Aug 12, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Hepatitis B Virus

Summary

Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Male or female, age ≥18 years old
  • HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog
  • Willing and able to provide written informed consent
  • Affiliated with a social securityregimen
  • Male or female, age between 18 and 80 years
  • Willing and able to provide written informed consent

Exclusion Criteria9

  • Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer)
  • Acute hepatitis in the year preceding recruitment
  • Other liver diseases : alcohol, obesity (BMI\>30), diabetes, metabolic syndrome (dyslipidemia and/or known hypertension) - Underlying immunological or cancerous diseases
  • Patient with a disability that prevents him/her from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship
  • Pregnant or breast-feeding women.
  • A healthy volunteer whose vaccination status does not match that expected on the basis of serological results
  • Positive blood pregnancy test on inclusion
  • Positive HCV, HIV or HDV test in a patient
  • Positive HBV, HCV, HIV or HDV test in a healthy volunteer

Interventions

OTHERblood sample HBV patient

During a boold sample at only one follow up visit: * 3 tubes EDTA 10 ml per patient * 1 tube "Paxgene" 1ml * 2 dry tube per patient

OTHERblood sample healthy volunteers

* 3 tubes EDTA ideally age and sex matched to CHB patient. * 1 tube "Paxgene" 1ml * 2 dry tube

Locations(3)

Centre d'Investigation Clinique

Limoges, France

Limoges University Hospital

Limoges, France

Hospice civils de Lyon

Lyon, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06853886